Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin

Suzuki, Yasuhito; Tanino, Yoshinori; Nikaido, Takefumi; Minemura, Hiroyuki; Umeda, Takashi; Rikimaru, Mami; Onuma, Takumi; Naito, Shotaro; Takiguchi, Yoshinori; Tomita, Haruyoshi; Kawamata, Takaya; Togawa, Ryuichi; Sato, Yuki; Uematsu, Manabu; Morimoto, Julia; Kitakawa, Kadzuhiro; Tsukada, Yasuhiko; Nakamura, Kiwamu; Kanemitsu, Keiji; Iseki, Ken; Shibata, Yoko

doi:10.2169/internalmedicine.6326-20

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 361 , 362 In a randomized, controlled trial including 84 COVID-19 patients, IVIg treatment did not demonstrate any therapeutic benefits in severe cases; however, a significant positive relationship between the number of days from admission to IVIg treatment and the length of hospitalization was observed, 363 which indicated the potential clinical benefit of IVIg administration during the early stage of COVID-19. In contrast, Suzuki et al 364 reported the potential efficacy of IVIg administration along with mechanical ventilation, methylprednisolone, favipiravir, ivermectin, and tocilizumab therapy in the late phase in an elderly patient with severe COVID-19.…”

Section: Interventions Targeting Multiple Cytokines and Pathwaysmentioning

confidence: 97%

The signal pathways and treatment of cytokine storm in COVID-19

Yang

Xie

et al. 2021

Sig Transduct Target Ther

439

413

View full text Add to dashboard Cite

The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis and is more devastating than any other previous infectious disease. It has affected a significant proportion of the global population both physically and mentally, and destroyed businesses and societies. Current evidence suggested that immunopathology may be responsible for COVID-19 pathogenesis, including lymphopenia, neutrophilia, dysregulation of monocytes and macrophages, reduced or delayed type I interferon (IFN-I) response, antibody-dependent enhancement, and especially, cytokine storm (CS). The CS is characterized by hyperproduction of an array of pro-inflammatory cytokines and is closely associated with poor prognosis. These excessively secreted pro-inflammatory cytokines initiate different inflammatory signaling pathways via their receptors on immune and tissue cells, resulting in complicated medical symptoms including fever, capillary leak syndrome, disseminated intravascular coagulation, acute respiratory distress syndrome, and multiorgan failure, ultimately leading to death in the most severe cases. Therefore, it is clinically important to understand the initiation and signaling pathways of CS to develop more effective treatment strategies for COVID-19. Herein, we discuss the latest developments in the immunopathological characteristics of COVID-19 and focus on CS including the current research status of the different cytokines involved. We also discuss the induction, function, downstream signaling, and existing and potential interventions for targeting these cytokines or related signal pathways. We believe that a comprehensive understanding of CS in COVID-19 will help to develop better strategies to effectively control immunopathology in this disease and other infectious and inflammatory diseases.

show abstract

Section: Interventions Targeting Multiple Cytokines and Pathwaysmentioning

confidence: 97%

The signal pathways and treatment of cytokine storm in COVID-19

Yang

Xie

et al. 2021

Sig Transduct Target Ther

439

413

View full text Add to dashboard Cite

show abstract

“…Further, a significant correlation between IVIG treatment and increased survival rate and decreased COVID-19 progression has been shown ( 283 ). Moreover, the potential benefit of IVIG administration along with antiviral drugs and mechanical ventilation in severe COVID-19 patients has been reported ( 257 ). Conversely, IVIG administration, along with hydroxychloroquine and lopinavir/ritonavir, in the treatment of severe COVID-19 cases, has not been supported by recent findings ( 301 ).…”

Section: Therapeutic Approaches To Covid-19mentioning

confidence: 99%

Immune responses in mildly versus critically ill COVID-19 patients

et al. 2023

View full text Add to dashboard Cite

The current coronavirus pandemic (COVID-19), caused by SARS-CoV-2, has had devastating effects on the global health and economic system. The cellular and molecular mediators of both the innate and adaptive immune systems are critical in controlling SARS-CoV-2 infections. However, dysregulated inflammatory responses and imbalanced adaptive immunity may contribute to tissue destruction and pathogenesis of the disease. Important mechanisms in severe forms of COVID-19 include overproduction of inflammatory cytokines, impairment of type I IFN response, overactivation of neutrophils and macrophages, decreased frequencies of DC cells, NK cells and ILCs, complement activation, lymphopenia, Th1 and Treg hypoactivation, Th2 and Th17 hyperactivation, as well as decreased clonal diversity and dysregulated B lymphocyte function. Given the relationship between disease severity and an imbalanced immune system, scientists have been led to manipulate the immune system as a therapeutic approach. For example, anti-cytokine, cell, and IVIG therapies have received attention in the treatment of severe COVID-19. In this review, the role of immunity in the development and progression of COVID-19 is discussed, focusing on molecular and cellular aspects of the immune system in mild vs. severe forms of the disease. Moreover, some immune- based therapeutic approaches to COVID-19 are being investigated. Understanding key processes involved in the disease progression is critical in developing therapeutic agents and optimizing related strategies.

show abstract

“…1 study was found by manually searching ( Zeng et al, 2020 ).Of these, 1 meeting abstract, 2 not written in the English language, 40 not relevant, 2 reviews were excluded. The full text of 33 remained studies was assessed for eligibility and 12 case reports or case series ( Horii et al, 2020 ; Inoue et al, 2020 ; Ito et al, 2020 ; Nakamura et al, 2020 ; Scarpati, 2020 , Shibata et al, 2020 ; Shimazu et al, 2020 ; Zeng et al, 2020a ; Fukada et al, 2021 ; Sumimoto et al, 2021 ; Suzuki et al, 2021 ; Yamaya et al, 2021 ), 2 studies that did not report the results clearly ( Miyagami et al, 2021 ; Takeshita et al, 2021 ), 3 studies that did not classify patients based on disease severity ( Frix et al, 2020 ; Chen et al, 2021a ; Scotto et al, 2021 ) and 1 preprint study ( Alimova et al, 2020 ) were excluded. Finally, 15 studies identified as relevant and entered the quality assessment ( Awano et al, 2020 , d'Alessandro et al, 2020a , d'Alessandro and Cameli, 2020 , d'Alessandro et al, 2020b ; Frix et al, 2020 ; jp, 2020 , Saito et al, 2020 ; Wang et al, 2020 ; Xue et al, 2020 ; Anai et al, 2021 ; Bergantini et al, 2021 ; Chen et al, 2021 , d’Alessandro et al, 2021 ; Deng et al, 2021 ; He et al, 2021 ; Peng et al, 2021 ; Scotto et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses

Naderi

Rahimzadeh

2022

Virology

View full text Add to dashboard Cite

Background Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells, and has been proposed as a marker of COVID-19 and the severity of the disease. Here, we performed a meta-analysis to determine whether KL-6 could be used as a prognostic factor for severe COVID-19. Methods PubMed, Cochrane and Google Scholar were searched until April 20, 2021, and 7 studies were included. KL-6 was considered as the outcome and pooled in meta-analyses. Results All included studies compared KL-6 in severe and non-severe patients. Serum KL-6 was higher in severe COVID-19 patients compared to non-severe (n = 6; SMD = 1.25; 95% CI: 0.99–1.5; P < 0.001) and healthy controls (n = 4; SMD = 3.07; 95% CI: 1.36–4.8; P < 0.001). Conclusion This data collection revealed the potential clinical significance of KL-6 as a non-expensive predictive biomarker in severe COVID-19 and for the categorization of COVID-19 clinical severity.

show abstract

Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin

Cited by 6 publications

References 17 publications

The signal pathways and treatment of cytokine storm in COVID-19

The signal pathways and treatment of cytokine storm in COVID-19

Immune responses in mildly versus critically ill COVID-19 patients

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses

Contact Info

Product

Resources

About